Back to Search Start Over

Cost-Effectiveness Analysis of CAB-LA for PrEP in the United States.

Source :
American Journal of Managed Care. 2023 Supplement, p1-7. 7p.
Publication Year :
2023

Abstract

The article presents a cost-effective analysis of APRETUDE (cabotegravir 200 mg/mL) extended-release injectable suspension for pre-exposure prophylaxis (PrEP) in the U.S. Topics discussed include risk of drug resistance with use of APRETUDE for HIV-1 PrEP in undiagnosed early HIV-1 infection, cost effectiveness analysis of cabotegravir long-acting (CAB-LA) for PrEP in the U.S., and important safety information for APRETUDE.

Subjects

Subjects :
*HIV prevention
*ANTI-HIV agents
*PRE-exposure prophylaxis
*COST effectiveness
*CONTROLLED release preparations
*ELIGIBILITY (Social aspects)
*PHARMACY information services
*PATIENT safety
*ADULTS
*ADOLESCENCE

Details

Language :
English
ISSN :
10880224
Database :
Academic Search Index
Journal :
American Journal of Managed Care
Publication Type :
Academic Journal
Accession number :
161640290

Tools

Authors Abstract Subjects Details